Blood related pharmaceuticals
Location: Finland
Total raised: $12.82M
Investors 1
| Date | Name | Website |
| - | Innovestor | innovestor... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.06.2026 | - | $5.56M | European I... |
| 03.02.2025 | - | $7.25M | - |
Mentions in press and media 8
| Date | Title | Description |
| 22.06.2026 | Aplagon Fuels Advanced Clinical Trials for Pioneering Vascular Therapy | Aplagon, a Helsinki-based biotech, secured €4.8M in financing. This vital capital expands its Phase 2 clinical program for APAC. The therapy targets arteriovenous fistula maturation failure in end-stage kidney disease patients. APAC, a firs... |
| 18.06.2026 | Aplagon Raises €4.8 Million To Broaden Phase 2 Trials Of APAC Therapy | Aplagon announced that it has closed a €4.8 million financing round, equal to about $5.6 million, to support the expansion of its APAC clinical development program. The financing will support a new Phase 2 clinical program evaluating APAC f... |
| 17.06.2026 | Why Outsourcing Accounting Is the Smartest Financial Move for Growing Property Managers | Property management sits at the intersection of real estate, operations, and finance. For small to mid-sized operators, that intersection can get crowded fast. Between tracking security deposits, reconciling rent rolls, filing trust account... |
| 17.06.2026 | Aplagon Raises €4.8M in Financing | Aplagon, a Helsinki, Finland-based clinical-stage biotechnology company developing APAC, an antiplatelet and anticoagulant therapy for treating thrombo-inflammatory diseases, raised EUR 4.8M (approx. USD 5.6M) in funding. The round was led ... |
| 03.02.2025 | Aplagon's €7 Million Boost: A New Dawn for Thrombo-Inflammatory Treatments | In the world of biopharmaceuticals, innovation is the lifeblood. Aplagon, a Helsinki-based company, has just secured a significant €7 million in funding. This financial injection comes at a crucial time as Aplagon pushes forward with its gr... |
| 03.02.2025 | HealthTech Aplagon announces €7 million for thrombo-inflammatory diseases | HealthTech Aplagon, a Helsinki-based clinical stage biopharmaceutical company developing a first-in-class therapeutic APAC for thrombo-inflammatory diseases, announced today it has closed a €7 million financing. The funding round was led by... |
| 03.02.2025 | Aplagon Raises EUR7M in Financing | Aplagon, a Helsinki, Finland-based clinical stage biopharmaceutical company, raised €7M in financing. The round was led by new investors Fåhraeus Startup and Growth AB (FSG), and European Innovation Council (EIC) Fund, joined by Finnish inv... |
| - | Aplagon | “Aplagon – Pioneering first-in-class treatments for patients with thromboinflammatory diseases” |